Clinical Blog
Published: August 25, 2022

Navigating Outcomes-Based Deals: Better Disease Management Starts With Better Measurement

Healthcare is at an inflection point. In the United States, value-based models continue to grow, with value-based contracts expected to account for 22% of insured lives by 2025 – up 7% from current figures.1 At the same time, rising healthcare costs and changing government incentives are contributing to shifts in provider and payer demand.

So, what does all of this mean for pharmaceutical and life sciences companies? 

Up to this point, the pharmaceutical industry has largely been able to sell their commercial products to buyers at flat, per-unit prices they’ve negotiated themselves. This is a markedly different model than payers and providers encounter in value-based contracts, and as the industry shifts more toward value-based pricing, payers are beginning to demand that pharmaceutical and life sciences companies mirror outcomes-based pricing models. 

In the respiratory space, AstraZeneca executed more than 35 outcomes-based agreements for its asthma and COPD inhaler medication, Symbicort. These agreements came just after AstraZeneca faced significant declines in Symbicort sales due to challenging market conditions. Considering the sustained market challenges and healthcare’s steady trajectory toward value-based care, other large pharmaceutical companies will likely follow suit. 

Outcomes-based deals between pharmaceutical companies and payers make sense in an industry increasingly focused on providing measurable improvements in patients’ health. How pharmaceutical companies prove these outcomes is critical, given the variety of factors that impact patient health in the real world, including how and if a patient is taking their medication as prescribed. If outcomes-based deals are based on efficacy as measured in clinical trials – a carefully-managed snapshot of time where enrolled patient behavior doesn’t always mimic real-world habits – pharmaceutical companies will have to do what they can to ensure patients are at least following prescribing information for their medication. 

Commercially-available digital health integrations like connected devices or integrated sensors can passively collect the objective data pharmaceutical companies need if they are to provide a truly complete picture of real-world outcomes, including medication usage trends. And when combined with a complete digital health platform, such as a mobile app and virtual coaching, the impact of connected drug delivery devices on patient outcomes becomes even greater, increasing the odds of driving higher patient engagement and motivating sustainable patient behavior change. 

Outcomes-based contracts between pharmaceutical companies, payers, and providers will only increase, and value-based care will become the primary payment model. As for pharmaceutical companies, the time to integrate digital solutions into their pipelines is now.

Discover how Propeller can help your organization integrate connected drug delivery. Email partnerships@propellerhealth.com

Attending the ERS International Congress 2022? Register for our exclusive education session on connected drug delivery devices.


1 McKinsey & Company, “The next frontier of care delivery in healthcare” (2022)

You Might Also Like

Pharma’s Biggest Takeaways From the 2023 J.P. Morgan Healthcare Conference

At J.P. Morgan’s 41st annual healthcare conference, there was no shortage of innovative discussions. We’ve rounded up some of the biggest themes from this year’s conference:

Connected drug delivery devices are gaining traction among top pharma companies

As medication non-adherence continues to plague the global life sciences industry – more than $600 billion in annual revenue is lost1 – many pharmaceutical companies are evaluating new approaches to improving patient engagement, including embedded sensors that capture data through drug delivery devices. One of the biggest selling points for organizations is that connected drug delivery devices can play a huge role in boosting adherence and compliance. Devices that can detect and capture data around patient-administered therapy, such as dose timing, volume, and technique, have become an increasingly popular choice among leading organizations. Patients are more likely to refill and take their medications on time, and correctly, if they can be prompted to do so and have a record of dosing history. 

In Value We Trust: How Health Systems Can Drive Population Health With Digital Solutions

With perpetually rising healthcare costs, soaring operating expenses, and plummeting profit margins, health systems are pressured to re-evaluate their care delivery models and shift their focus to value.

Implementing the right tools to enhance decision making and build care management capabilities for population health, risk stratification, and site-of-care optimization will be vital for navigating this actively evolving landscape. Digital health solutions are critical enablers of success, especially having demonstrated clinical and real-world outcomes in all reimbursement settings. 

In an outcomes-based payment model, health systems can leverage digital solutions to:

Raising the Volume: How Health Systems Can Overcome Economic Turmoil With Digital Solutions

A staggering 97% of medical practices experienced a negative financial impact at the beginning of the pandemic, including a 60% decrease in patient volume and a 55% decline in revenue.1 Nearly three years later, more than half of hospitals are still experiencing negative margins.2 

To ensure success in this actively evolving landscape, health systems must equip themselves with the right tools to enhance decision making and reduce administrative burden through frictionless clinician experiences. Digital health solutions are critical enablers of success, especially having demonstrated clinical and real-world outcomes in all reimbursement settings. 

In a traditional payment model, digital solutions can help health systems: